The new bladder cancer drug Balversa may now be prescribed in general hospitals in Korea.

According to industry sources, Janssen Korea’s FGFR-inhibiting urothelial carcinoma (bladder cancer) drug Balversa (erdafitinib) has recently passed the drug committees (DCs) of tertiary hospitals including Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital, as well as the drug committees of medical institutions such as Hallym University Kangnam Sacred Heart Hospital, National Cancer Center, and Cheonam National University Hwasun Hospital.

Balversa was approved by the Ministry of Food and Drug Safety in January 2022. However, it is still not reimbursed in Korea.